| NCT ID | NCT02863692 |
| Status | Recruiting |
| Phase | — |
| Sponsor | German CLL Study Group |
| Condition | CLL |
| Study Type | OBSERVATIONAL |
| Enrollment | 8,000 participants |
| Start Date | 2013-08 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 8,000 participants in total. It began in 2013-08 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T/Natural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformation
Eligibility Criteria
Inclusion Criteria (all must apply) 1. Confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK-LGL, HCL or Richter's transformation 2. 18 years of age or older 3. Signed, written informed consent 4. Presence of one or more of the following disease situations: * Newly diagnosed patients without treatment indication (eligible for watch and wait Approach Treatment within a clinical trial according to the AMG or status post participation in a clinical Trial) * Treatment with standard therapies approved for the eligible entities or status post treatment (outside of clinical trials) * Referral for evaluation the indication for HSCT * Relapsed disease status (even if first diagnosis was prior to activation of the registry) Exclusion Criteria 1. Patients without confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK- LGL, HCL or Richter's transformation 2. Cerebral dysfunction, legal incapacity
Contact & Investigator
Michael Hallek, MD
STUDY DIRECTOR
German CLL Study Group, Department I of Internal Medicine University Hospital Cologne
Frequently Asked Questions
Who can join the NCT02863692 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying CLL. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02863692 currently recruiting?
Yes, NCT02863692 is actively recruiting participants. Contact the research team at cllstudie@uk-koeln.de for enrollment information.
Where is the NCT02863692 trial being conducted?
This trial is being conducted at Dresden, Germany.
Who is sponsoring the NCT02863692 clinical trial?
NCT02863692 is sponsored by German CLL Study Group. The principal investigator is Michael Hallek, MD at German CLL Study Group, Department I of Internal Medicine University Hospital Cologne. The trial plans to enroll 8,000 participants.